- Two durable partial responses in checkpoint inhibitor-naive nasopharyngeal carcinoma and uveal melanoma patients in dose escalation of INBRX-106 in combination with Keytruda®

- Orphan-drug designation follows fast track designation granted to INBRX-109 in conventional chondrosarcoma

- Median progression-free survival (PFS) of 7.6 months and disease control rate of 87.5% observed in conventional chondrosarcoma patients in Phase 1

Registration-enabling study expected to begin dosing in the second or third quarter of this year

- Successful completion of initial public offering with net proceeds of $126 million; cash and cash equivalents of $128 million as of September 30th

- Disease control observed in 92% of patients

-INBRX-109 was well-tolerated; a maximum tolerated dose was not reached-

Inhibrx’s AAT-Fc therapeutic should benefit patients with enhanced efficacy and less frequent dosing